Peringatan Keamanan

Renal tubular nephropathy characterized by histological alterations and/or increases in BUN and serum creatinine was the primary dose-limiting toxicity associated with administration of adefovir dipivoxil in animals. Nephrotoxicity was observed in animals at systemic exposures approximately 3–10 times higher than those in humans at the recommended therapeutic dose of 10 mg/day.

Adefovir dipivoxil

DB00718

small molecule approved investigational

Deskripsi

Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.

Struktur Molekul 2D

Berat 501.4705
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 ± 1.65 hours.
Volume Distribusi * 392 ± 75 mL/kg [Vd at steady state, intravenous administration of 1.0 mg/kg/day] * 352 ± 9 mL/kg [Vd at steady state, intravenous administration of 3.0 mg/kg/day]
Klirens (Clearance) * 469 ± 99.0 mL/min [Patients with Unimpaired renal Function receiving a 10 mg single dose] * 356 ± 85.6 mL/min [Patients with mild renal impairement receiving a 10 mg single dose] * 237 ± 118 mL/min [Patients with moderate renal impairement receiving a 10 mg single dose] * 91.7 ± 51.3 mL/min [Patients with severe renal impairement receiving a 10 mg single dose]

Absorpsi

The approximate oral bioavailability of adefovir from HEPSERA is 59%. When a single oral 10 mg dose is given to chronic hepatitis B patients, the peak plasma concentration (Cmax) of adefovir was 18.4 ± 6.26 ng/mL. This occurred between 0.58 - 4 hours post dose (Tmax). The adefovir area under the plasma concentration-time curve (AUC0–?) was 220 ± 70.0 ng?h/mL. Food does not affect the exposure of adeforvir.

Metabolisme

Following oral administration, adefovir dipivoxil is rapidly converted to adefovir. 45% of the dose is recovered as adefovir in the urine over 24 hours at steady state following 10 mg oral doses. Adefovir is not a substrate of the cytochrome P450 enzymes.

Rute Eliminasi

Adefovir is renally excreted by a combination of glomerular filtration and active tubular secretion.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

756 Data
Foscarnet The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Adefovir dipivoxil.
Tenofovir disoproxil The serum concentration of Tenofovir disoproxil can be increased when it is combined with Adefovir dipivoxil.
Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Adefovir dipivoxil.
Tenofovir The serum concentration of Tenofovir can be increased when it is combined with Adefovir dipivoxil.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir dipivoxil.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Adefovir dipivoxil.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Adefovir dipivoxil.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Adefovir dipivoxil.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Adefovir dipivoxil.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Adefovir dipivoxil.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Adefovir dipivoxil.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Adefovir dipivoxil.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Adefovir dipivoxil.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Adefovir dipivoxil.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Adefovir dipivoxil.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Adefovir dipivoxil.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Adefovir dipivoxil.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Adefovir dipivoxil.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Adefovir dipivoxil.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Adefovir dipivoxil.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Adefovir dipivoxil.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Adefovir dipivoxil.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Adefovir dipivoxil.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Adefovir dipivoxil.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Adefovir dipivoxil.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Adefovir dipivoxil.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Adefovir dipivoxil.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Adefovir dipivoxil.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Adefovir dipivoxil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Pentamidine.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Mefenamic acid.
Naproxen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Naproxen.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Sulfasalazine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Phenylbutazone.
Meloxicam The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Carprofen.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Tacrolimus.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Etacrynic acid.
Ceforanide The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ceforanide.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Salicylic acid.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Acetylsalicylic acid.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Hydrochlorothiazide.
Balsalazide The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Balsalazide.
Cefditoren The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefditoren.
Atazanavir The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Atazanavir.
Colistimethate The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Colistimethate.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefuroxime.
Cefapirin The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefapirin.
Cefprozil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefprozil.
Olsalazine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Lumiracoxib.
Cefamandole The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefamandole.
Cefazolin The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefazolin.
Cefonicid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefonicid.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefoperazone.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefoxitin.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ceftizoxime.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Magnesium salicylate.
Salsalate The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Choline magnesium trisalicylate.
Cefepime The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefepime.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefacetrile.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefpodoxime.
Antrafenine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Antrafenine.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Aminophenazone.
Antipyrine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Antipyrine.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Tiaprofenic acid.
Lopinavir The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Lopinavir.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Etoricoxib.
Hydrolyzed Cephalothin The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Hydrolyzed Cephalothin.
Cephalothin Group The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cephalothin Group.
Oxyphenbutazone The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Oxyphenbutazone.
Latamoxef The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Latamoxef.
Nimesulide The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Nimesulide.
Benoxaprofen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Benoxaprofen.
Metamizole The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Metamizole.
Zomepirac The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Zomepirac.
Ceftobiprole The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ceftobiprole.
Cimicoxib The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cimicoxib.
Ceftaroline fosamil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ceftaroline fosamil.
Lornoxicam The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Lornoxicam.
Zaltoprofen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Zaltoprofen.
Azapropazone The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Azapropazone.
Parecoxib The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Parecoxib.
Salicylamide The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Salicylamide.
Kebuzone The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Kebuzone.
Isoxicam The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Isoxicam.
Indoprofen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Indoprofen.
Ibuproxam The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Ibuproxam.
Floctafenine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Floctafenine.
Fenbufen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Fenbufen.
Etofenamate The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Etofenamate.
Epirizole The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Epirizole.
Cefaloridine The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefaloridine.
Cefminox The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefminox.
Dexibuprofen The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Dexibuprofen.
Droxicam The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Droxicam.
Tolfenamic acid The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Tolfenamic acid.
Firocoxib The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Firocoxib.

Target Protein

Protein P P

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 8 • International brands: 18
Produk
  • Aa-adefovir
    Tablet • 10 mg • Oral • Canada • Generic • Approved
  • Adefovir Dipivoxil
    Tablet • 10 mg/1 • Oral • US • Generic • Approved
  • Adefovir dipivoxil
    Tablet • 10 mg/1 • Oral • US • Generic • Approved
  • Hepsera
    Tablet • 10 mg/1 • Oral • US • Approved
  • Hepsera
    Tablet • 10 mg/1 • Oral • US • Approved
  • Hepsera
    Tablet • 10 mg • Oral • Canada • Approved
  • Hepsera
    Tablet • 10 mg • Oral • EU
  • Hepsera
    Tablet • 10 mg • Oral • EU
International Brands
  • A Di Xian — The United Laboratories Ltd
  • A Gan Ding — Fujian Guangsheng Tang
  • Adesera — Cipla
  • Adfovir — Sun Pharmaceutical Industries Ltd.
  • Ailuwei — Changzheng-Xinkai
  • Antiva — Square
  • Biovir — Ivax
  • Dai Ding — Tianjin Institute of Pharmaceutical Research
  • Dinghe — Lukang
  • Infovir — Incepta

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul